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sideration if the duals are treated as a homogenous group. The objective of this study 
was to compare elderly vs disabled duals across demographic, morbidity, health 
care utilization, and drug spending measures. Methods: Cross-sectional analysis 
comparing profiles of disabled (n= 90,894) and elderly (n= 126,752) fee-for-service 
beneficiaries with continuous 12-month dual-eligibility, or until alive in the 2007 
5% Medicare files. Chi-square and t-tests were conducted to measure statistically 
significant differences across measures of interest between elderly and disabled 
duals. Results: Elderly duals were more likely to be female and suffer from chronic 
conditions like CHF, while disabled duals were more likely to have mental disorders 
like depression. Disabled duals had significantly higher rates of ER use (8.4% vs 6.4%) 
and lower rate of hospitalization (31.9% vs 24.5%) than elderly duals. Compared to 
the disabled, elderly duals had significantly higher rates of Part D brand drug use 
(88% vs 81%), but lower use of drugs typically placed on Part D specialty tiers (10% 
vs 13%). Significant differences existed in the types of drug classes frequently used 
by the two groups. Large differences in spending across all types of medical services 
and drug categories across the two groups were observed. ConClusions: There 
are significant differences in demographic, morbidity, health care utilization, and 
drug spending measures across the elderly vs. disabled duals. Recognizing the dif-
ferences between sub-populations of dual eligibles is critically important and a “one 
size fits all” approach may unintentionally create hardships and be detrimental to 
the well-being of the duals.
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objeCtives: (1) To examine the impact of two medication review programs designed 
to decrease overall health care costs through optimizing medication therapy. The 
interventions are designed to promote proper prescribing in accordance with clini-
cal literature and national guidelines and counsel individual members with regard 
to their medication regimens; (2) To explore the use of randomized clinical trials 
to vet vendor proposed programs for improving health and reducing health care 
costs. Methods: Independence Blue Cross and their Pharmacy Benefit Manager, 
Catamaran jointly designed a randomized controlled trial to test the efficacy of 
two medication review programs. Medical and pharmacy claims data for members 
assigned to the intervention condition were analyzed daily for intervention opportu-
nities based on a complex set of rules. The rules identify members who may benefit 
from one or more of 14 potential therapy adjustments including drug-drug and 
drug-condition interactions, dose optimization, appropriateness of therapy, high 
risk medication in the elderly, and generic interchange. Once identified, Catamaran 
contacted prescribers via fax to recommend therapy adjustments. Verification of 
therapy changes were determined through claims reviews and prescriber feed-
back. Results: 39,138 members were randomly assigned to either the intervention 
or control. Results show that 28% of the clinical recommendations were adopted 
resulting in a reduction in pharmacy spend of $72,747 and a reduction in medi-
cal spend of $1 million. ConClusions: Catamaran’s medication review programs 
show significant medical and pharmacy cost savings while improving population 
health through appropriate management of prescription drugs. These programs 
are intended to help members avoid inappropriate or potentially dangerous medi-
cations, increase medication adherence, close gaps in care, optimize medication 
therapy, and lower medical costs. Moreover, we demonstrate that a collaborative 
approach to evaluating a proposed vendor solution resulted in a cost effective RCT 
that offers maximum benefit to members and the health plan.
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objeCtives: This study assessed trends in state-level, fee-for-service Medicaid 
generic and brand drug utilization and expenditures, and pharmacy reimburse-
ment rates in the period 2010-2012. Methods: Medicaid fee-for-service outpatient 
pharmacy utilization and expenditures, and reimbursement rates (ingredient cost 
and dispensing fees) for the years 2010-2012 were extracted from State-level data 
provided from the Centers for Medicare and Medicaid Services. Current dollars 
were converted to 2012 dollars using the U.S. consumer price index. Descriptive 
analyses were performed for all variables. Confidence intervals (95%) were calcu-
lated for continuous variables. Linear regression analysis was performed to assess 
the relationship between ingredient cost, dispensing fees and drug utilization. The 
significance level for variables was 0.05. Results: Fee-for-service Medicaid expen-
ditures (n= 42 states) decreased from $23.0 billion in 2010 to $18.7 billion in 2012 
(14.9% decrease) and drug utilization decreased from 351.2 to 281.4 million claims 
in the same period (19.9% decrease). Generic utilization represented 70.6% of total 
prescriptions in 2010 and 75.4% in 2012, and generic expenditures represented 17.9% 
of total expenditures in 2010 and 18.0% in 2012. The average reimbursement of 
generic drugs was $17.89 (95%CI= $16.63-$19.14) in 2010 and decreased to $16.91 
(95%CI= $14.48-$19.34) in 2012, while the average reimbursement of brand drugs 
increased from $197.34 (95%CI= $184.74-$209.94) to $235.93 (95%CI= $218.07-$253.79). 
The average pharmacy dispensing fee increased from $4.34±$1.24 to $4.60±$2.56 
for generics and from $4.10±$1.19 to $4.38±$2.58 for brands. We found no statis-
tically significant relationship between the number of claims or the total state 
expenditures, and the dispensing fee or the average ingredient cost. ConClusions: 
Pharmacy expenditures decreased in the period 2010-2012 due to a decrease in the 
volume of prescriptions and the reduction in generic prices. Differences in dispens-
ing fees and ingredient costs among Medicaid programs were independent of total 
prescription volume. Increases in generic utilization could result in substantial 
savings to Medicaid programs.
complete claims 180 days pre and 720 days post index. Biologic claim clean period 
was 180 days pre-index. SQ biologic users with reported days supplies that were 
< 7 or > 90 days were excluded. Duration of action for infusion products was based 
on package inserts. Patients were censored after a gap of at least 90 days beyond 
the next expected re-fill interval. Results describe median time to discontinuation 
(Kaplan-Meier plots) covering 720 days. A Cox regression model assessed the IV vs 
SQ hazard ratio. Results: 1830 IV and 5934 SQ patients were identified. Diagnoses 
in the IV cohort included 29.9% IBD, 50.4% RA, 3.2% PsA and 16.5% any combination 
or none. Corresponding diagnoses for the SQ cohort were 10.9%, 49.5%, 8.9% and 
30.7% respectively. IV and SQ cohorts were similar for gender and co-morbidities, 
and IV cohort was slightly older with slightly higher use of concomitant methotrex-
ate and steroids than SQ cohort in RA and PsA. Overall, median time to discontinu-
ation for IV was 388 days vs SQ at 191 days, and was significantly longer for IV vs 
SQ across all indications. Within SQ cohort, RA patients (203 days) had the longest 
persistence vs other indications. For IV cohort, it was PsA patients (471 days). IBD 
patients tended to have the shortest persistence. Cox regression showed hazard for 
SQ discontinuation 1.61(CI:1.51-1.72) times greater than for IV, controlling for age, 
gender and co-morbidities. ConClusions: IV consistently demonstrated longer 
times to discontinuation vs. SQ across indications studied.
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objeCtives: This study sought to examine the effect of pharmacists’ visits to home-
bound patients on the elimination of unused drugs. Methods: We conducted a 
survey with pharmacies throughout Japan that provided home visiting service, 
requesting their home-visiting pharmacists to respond to questions regarding 
their work with up to five homebound patients (the survey period was January 15, 
2013 through the end of February, 2013). Main survey questions were: (1) have you 
handled unused drugs since the home visits started? and (2) how did you handle 
the unused drugs? For (2), we conducted case studies by asking the pharmacists 
to choose the case that impressed them most and describe chronologically the 
unused drugs involved, the action taken, and what followed the action. Results: 
Data on 5,447 patients was collected from 1,890 pharmacies throughout Japan (col-
lection rate: 56.9%). Pharmacists handled unused drugs of 2,484 patients (45.6%). 
1,718 patients (3,593 cases) were qualified for analysis. In 2,334 cases (65%), the 
incidences of unused drugs were eliminated after pharmacists’ intervention. In 
782 cases (21.8%), unused drugs were discarded, while in 2,624 cases (73.0%), the 
number of days of drug administration was adjusted. In 21 cases (0.6%), drugs were 
both discarded and had the number of days adjusted. There were no responses 
for 166 cases (4.6%). The total price of the unused drugs that were eliminated was 
approximately 6,800,000 yen (4,000 yen/person). The top three illnesses with the 
best effects from the elimination of unused drugs were chronic respiratory failure 
(approximately 16,500 yen/person), Parkinson’s disease (approximately 5,000 yen/
person), and cancer (approximately 4,300 yen/person). ConClusions: We were 
able to confirm the economic effect of eliminating unused drugs by pharmacists’ 
home visits.
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objeCtives: This analysis examined potential risk factors for adverse drug reac-
tion (ADR)-related hospitalizations and compared seniors’ drug therapy pre-
admission and post-discharge to see whether hospitalization led to changes in 
drug therapy. Methods: This analysis used hospital discharge data from the 
Discharge Abstract Database and drug claims data from the National Prescription 
Drug Utilization Information System Database to assess potential risk factors for 
ADR hospitalizations among seniors on public drug programs in Alberta, Manitoba 
and P.E.I. Results: The number of drugs was the most significant risk factor, with 
seniors taking 15 or more drugs 6.4 times more likely than seniors taking fewer 
than 5 drugs to have been hospitalized for an ADR. Other factors associated with 
hospitalizations for ADRs were patient age and being hospitalized in the previous 
year. The relationship between new drug starts and ADR-related hospitalizations 
varied by drug class. 33.2% of seniors hospitalized for an opioid-related ADR started 
taking an opioid within 30 days of hospitalization, while only 28.2% of seniors hos-
pitalized for an anticoagulant-related ADR started an anticoagulant within a year of 
hospitalization. ConClusions: Although it is often necessary for seniors to take 
multiple drugs to manage their chronic conditions, regular medication reviews can 
help reduce the risk of adverse events including drug interactions. A high proportion 
of the hospitalizations related to anticoagulant ADRs occurred more than a year 
after starting therapy, which underscores the importance of ongoing monitoring.
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objeCtives: Dual-eligibles are elderly and disabled under age 65 individuals who 
are entitled to Medicare and Medicaid. CMS has instituted a state demonstration 
program to test capitated and managed FFS financial alignment care models for 
duals. Limited research exists on the differences between the two dual subpopula-
tions – elderly and disabled, which could prove problematic for benefit design con-
